|
|
Vaccine Detail
|
PR-151 Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: PR-151 Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007082
- Type: Peptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: p53
- mouse Trp53
gene engineering:
- Preparation: The vaccine uses viral vector to deliver full-length p53 has the potential to generate sustained antigen expression and the presentation of numerous antigenic determinants on different HLA molecules (Hardwick et al., 2018).
- Description: This is for Lung Cancer (NCT00049218).A tumor-specific peptide encoded by patient-specific mutant p53 oncogene with potential immunostimulatory properties. The peptide (LPTGQDL) contains a frame shift mutation at amino acid position 134. It was used to pulse dendritic cells, which are then used in the adoptive immunotherapy setting and may stimulate the host immune system to mount a specific cytotoxic T lymphocyte response against tumor cells expressing the p35 mutation (Hardwick et al., 2018; NCIT_C38121).
|
| Host Response |
|
|
| References |
Hardwick et al., 2018: Hardwick NR, Frankel P, Ruel C, Kilpatrick J, Tsai W, Kos F, Kaltcheva T, Leong L, Morgan R, Chung V, Tinsley R, Eng M, Wilczynski S, Ellenhorn JDI, Diamond DJ, Cristea M. p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018; 24(6); 1315-1325. [PubMed: 29301826].
NCIT_C38121: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38121]
NCT00049218: [https://clinicaltrials.gov/ct2/show/NCT00049218]
|
|
